Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

Jaana M. Hartikainen | S. Cross | M. Beckmann | P. Fasching | A. Olshan | C. Vachon | K. Czene | P. Hall | A. Howell | F. Couch | A. Schneeweiss | H. Brenner | J. Chang-Claude | S. Chanock | M. García-Closas | D. Hunter | A. Wolk | R. Prentice | G. Giles | J. Hopper | C. Haiman | E. John | T. Dörk | M. Southey | A. Cox | D. Easton | P. Kraft | R. Tamimi | G. Rennert | P. Pharoah | D. Lambrechts | L. Le Marchand | N. Orr | S. Buys | H. Brauch | V. Kristensen | A. Ziogas | H. Anton-Culver | P. Guénel | A. Dunning | R. Luben | D. Eccles | D. Evans | G. Chenevix-Trench | S. Bojesen | B. Nordestgaard | H. Nevanlinna | R. Milne | U. Hamann | J. Beesley | A. Mannermaa | J. Hartikainen | M. Shah | C. Clarke | A. Lindblom | K. Michailidou | J. Dennis | M. Schmidt | M. Bolla | Qin Wang | T. Muranen | R. Schmutzler | S. Canisius | S. F. Nielsen | H. Flyger | T. Truong | E. Sawyer | I. Tomlinson | I. Andrulis | A. Mulligan | S. Margolin | M. Hooning | A. Jager | J. Stone | A. Ekici | V. Arndt | A. Swerdlow | R. Winqvist | M. Grip | T. Brüning | P. Peterlongo | A. Jakubowska | J. Lubiński | M. Eriksson | T. Park-Simon | M. Dwek | W. Tapper | M. Lush | D. Campa | F. Canzian | W. Newman | P. Auer | R. Kaaks | A. Kurian | R. Keeman | S. Hart | J. Lacey | M. Troester | D. Plaseska-Karanfilska | E. Hahnen | R. Roylance | M. Ruebner | W. Janni | M. Daly | A. Jung | M. Manoochehri | Stella Koutros | B. Caan | J. García-Saenz | L. Fritschi | M. Terry | R. Tollenaar | B. Peissel | M. Linet | H. Rennert | Christopher Scott | N. Håkansson | Amber N. Hurson | M. Gago-Domínguez | M. Martínez | J. Castelao | J. Martens | Wei He | L. Dossus | C. Kitahara | A. Romero | T. Ahearn | L. B. Beane Freeman | S. Behrens | A. Eliassen | D. Mavroudis | N. Presneau | B. Rack | V. Rhenius | E. Saloustros | T. Cheng | H. Surowy | K. Prajzendanc | S. Smichkoska | A. Morra | Alpa V. Patel | Lauren R. Teras | Hampus Olsson | Heiko Becher | A. Augustinsson | M. Keupers | M. Escala-Garcia | Reiner Hoppe | Melanie Gündert | J. E. Castelao | A. Hartmann | A. Patel | Sarah V Colonna | S. Koutros | J. Stone | Thérèse Truong | P. Hall | D. Evans | Mervi Grip | D. Evans | D. Hunter | Qin Wang | Thérèse Truong | D. Plaseska‐Karanfilska | D. Evans

[1]  Gary D. Bader,et al.  A network analysis to identify mediators of germline-driven differences in breast cancer prognosis , 2020, Nature Communications.

[2]  Jack A. Taylor,et al.  Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses , 2019, bioRxiv.

[3]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Whittemore,et al.  Genome-wide association study of germline variants and breast cancer-specific mortality , 2019, British Journal of Cancer.

[5]  Helen E. Parkinson,et al.  The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019 , 2018, Nucleic Acids Res..

[6]  N S El Saghir,et al.  4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  T. Ochiya,et al.  Emerging roles of long non‐coding RNA in cancer , 2018, Cancer science.

[8]  N. Howlader,et al.  Differences in Breast Cancer Survival by Molecular Subtypes in the United States , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[9]  Zhao Zhang,et al.  PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types , 2017, Nucleic Acids Res..

[10]  Erdogan Taskesen,et al.  Functional mapping and annotation of genetic associations with FUMA , 2017, Nature Communications.

[11]  P. Fasching,et al.  Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women , 2017, Nature Communications.

[12]  M. Veta,et al.  Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study , 2017, BMJ Open.

[13]  Michael Jones,et al.  Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer , 2017, Nature Genetics.

[14]  A. Børresen-Dale,et al.  Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters. , 2017, The American journal of pathology.

[15]  T. Wolfsberg,et al.  Mapping Complex Traits in a Diversity Outbred F1 Mouse Population Identifies Germline Modifiers of Metastasis in Human Prostate Cancer. , 2017, Cell systems.

[16]  M. Boutros,et al.  Wnt signaling in cancer , 2016, Oncogene.

[17]  A. Lánczky,et al.  miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients , 2016, Breast Cancer Research and Treatment.

[18]  Dennis J. Hazelett,et al.  The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[19]  Jane E. Carpenter,et al.  Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer , 2016, Nature Communications.

[20]  Howard Y. Chang,et al.  Long Noncoding RNAs in Cancer Pathways. , 2016, Cancer cell.

[21]  Yong Peng,et al.  The role of MicroRNAs in human cancer , 2016, Signal Transduction and Targeted Therapy.

[22]  Jaana M. Hartikainen,et al.  Common germline polymorphisms associated with breast cancer-specific survival , 2015, Breast Cancer Research.

[23]  P. Fasching,et al.  The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients , 2015, Oncotarget.

[24]  Jaana M. Hartikainen,et al.  Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy , 2015, Breast Cancer Research.

[25]  Xifeng Wu,et al.  Identification of Novel Genetic Markers of Breast Cancer Survival , 2015 .

[26]  F. Couch,et al.  A Genome Wide Meta-Analysis Study for Identification of Common Variation Associated with Breast Cancer Prognosis , 2014, PloS one.

[27]  O. Yersal,et al.  Biological subtypes of breast cancer: Prognostic and therapeutic implications. , 2014, World journal of clinical oncology.

[28]  Matthias W. Beckmann,et al.  2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy , 2014, Nature Communications.

[29]  Jelle J. Goeman,et al.  Multiple hypothesis testing in genomics , 2014, Statistics in medicine.

[30]  E. Alba,et al.  The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer. , 2014, Cancer treatment reviews.

[31]  N. Crawford,et al.  Germline Genetic Variation Modulates Tumor Progression and Metastasis in a Mouse Model of Neuroendocrine Prostate Carcinoma , 2013, PloS one.

[32]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[33]  Daniel J. Park,et al.  19p13.1 is a triple-negative-specific breast cancer susceptibility locus. , 2012, Cancer research.

[34]  Yusuke Nakamura,et al.  A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese , 2022 .

[35]  Paul Polakis,et al.  Wnt signaling in cancer. , 2012, Cold Spring Harbor perspectives in biology.

[36]  C. Croce,et al.  Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA , 2012, Proceedings of the National Academy of Sciences.

[37]  Jane E. Carpenter,et al.  Common breast cancer susceptibility loci are associated with triple-negative breast cancer. , 2011, Cancer research.

[38]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[39]  R. Carlson,et al.  Principles of Breast Cancer Therapy , 2010 .

[40]  A. Phipps,et al.  Breast Cancer Biology and Clinical Characteristics , 2010 .

[41]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[42]  M. Stephens,et al.  Bayesian statistical methods for genetic association studies , 2009, Nature Reviews Genetics.

[43]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[44]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[45]  N. Crawford,et al.  The origins of breast cancer prognostic gene expression profiles. , 2009, Cancer research.

[46]  A. Sigurdsson,et al.  Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer , 2008, Nature Genetics.

[47]  N. Crawford,et al.  Bromodomain 4 activation predicts breast cancer survival , 2008, Proceedings of the National Academy of Sciences.

[48]  Jinghui Zhang,et al.  Rrp1b, a New Candidate Susceptibility Gene for Breast Cancer Progression and Metastasis , 2007, PLoS genetics.

[49]  Jon Wakefield,et al.  A Bayesian measure of the probability of false discovery in genetic epidemiology studies. , 2007, American journal of human genetics.

[50]  K. Czene,et al.  Is breast cancer prognosis inherited? , 2007, Breast Cancer Research.

[51]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[52]  K. Hunter,et al.  Host genetics influence tumour metastasis , 2006, Nature Reviews Cancer.

[53]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[54]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[55]  J. Shimazaki,et al.  Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  M. Hung,et al.  β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .